A look back at the week's news.
The fact that copper-containing intrauterine devices (Cu-IUDs) can increase bleeding and discontinuation rates compared to levonorgestrel-releasing IUDs (LNG-IUDs) does not mean clinicians should steer patients toward the latter, according to a review published in BMC Women’s Health. Due to high satisfaction rates with both devices, authors recommend letting patients choose based on their needs and preferences.
Three months after cooper intrauterine device (IUD) insertion, nearly 1/3 of women were diagnosed with vulvovaginal candidiasis, compared to nearly 25% of women who received a hormonal IDU, according to a prospective study published in the journal Cellular and Molecular Biology.
A research study examined the role of a medicated feminine wash as an adjunct treatment for candidiasis.
Katie Huffling, DNP, RN, CNM, FAAN, shares how you can help educate your pregnant patients to become more educated consumers.
Research in Menopause connects history of physical/sexual abuse, financial instability with worse menopausal symptoms and overall wellbeing at midlife.
An advisory panel for the US Food and Drug Administration voted 14-1 to withdraw 17α-hydroxyprogesterone caproate (Makena; Covis Pharma) from the market.
Rebecca Thurston, PhD, sits down to discuss the latest news from the North American Menopause Society Annual Meeting.
Katie Huffling, DNP, RN, CNM, FAAN, sits down to discuss her presentation at the Nurse Practitioners in Women’s Health (NPWH) 25th Annual Conference in Houston, Texas from September 28 to October 2022.